Physician profile
Bruce Jay Berwald
NPI 1376647644
$5,281.93
in general payments reported to CMS, 2019-2025
32 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $611 · 2021: $768 · 2022: $629 · 2023: $785 · 2024: $813 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $804.22 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $675.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $664.31 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals Lp | $427.08 | 2019-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $340.66 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $324.54 | 2021-2025 | Rexulti |
| Amarin Pharma, INC. | $308.43 | 2019-2022 | |
| Pfizer INC. | $241.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $177.23 | 2019-2023 | Xarelto |
| Corcept Therapeutics | $122.82 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $118.86 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.98 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.25 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $79.18 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.46 | 2020-2024 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $72.63 | 2021-2024 | Livalo, Seglentis, Zoryve |
| Kvk-Tech, INC. | $67.15 | 2025 | |
| Allergan, INC. | $60.88 | 2020 | |
| Exact Sciences Corporation | $55.86 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $55.38 | 2020-2021 | |
| Glaxosmithkline, LLC. | $51.54 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Eisai INC. | $50.95 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.84 | 2024-2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.59 | 2022 | |
| Astellas Pharma US INC | $39.43 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $37.88 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.27 | 2023-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $25.00 | 2025 | Rexulti |
| Optos, INC. | $22.97 | 2021 | |
| Axsome Therapeutics, INC. | $21.67 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $19.42 | 2024 | Fanapt |
| Alexion Pharmaceuticals, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Berwald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.